Press Release July 14, 2022

Goodwin Bolsters Global Life Sciences Practice with Partner Morag Peberdy in London

Global law firm Goodwin today announced that partner Morag Peberdy will join its London office in the Life Sciences practice as the firm continues its commitment to provide best-in-class services to biotechnology, pharmaceutical, and medical technology companies throughout all stages of the life cycle. 

“As part of our mission to be the destination law firm for those operating in the life sciences space, it is vital that we continue to offer our clients an international practice with market-leading capabilities in corporate, licensing, intellectual property and regulatory matters,” said Mitchell Bloom, chair of Goodwin’s Life Sciences practice. “Morag brings deep experience advising investors and companies on complex licensing matters that will further enhance our excellent existing platform.”

Peberdy has over 20 years’ experience advising pharmaceutical and biotech companies, ranging from start-ups through to large international corporates, on drafting and negotiating intellectual property-related agreements, with particular expertise in foundational IP licenses and strategic collaborations.

Peberdy is the latest addition to Goodwin’s market-leading Life Sciences practice as it continues its growth to meet client demand. In the past three years, the practice has nearly doubled its headcount to more than 225 lawyers, science advisors, and patent agents. During this time, the practice expanded globally to Cambridge, UK, Paris, Los Angeles, and Santa Monica, and added additional regulatory, corporate, licensing, and intellectual property depth in London, Hong Kong, Silicon Valley, San Francisco, Washington, D.C., New York, and Boston.

Goodwin’s recent representative life sciences work includes advising Moderna from inception through the rollout of its COVID-19 vaccine; advising Biocon Biologics on its agreement to acquire Viatris’ biosimilars business for up to $3.335 billion, representing AbCellera Biologics on its $555.5 million IPO, one of biotech’s largest IPOs; and representing MyoKardia on its $13.1 billion acquisition by Bristol Myers Squibb.